Please login to the form below

Not currently logged in
Email:
Password:

ovarian cancer

This page shows the latest ovarian cancer news and features for those working in and with pharma, biotech and healthcare.

GSK upbeat on its return to oncology market

GSK upbeat on its return to oncology market

Due for readout in late 2019, the PRIMA trial is looking at Zejula in first line ovarian cancer, regardless of any biomarker status. ... Of greatest potential are those with BRCA wild-type tumours and patients with homologous recombination deficiency

Latest news

More from news
Approximately 32 fully matching, plus 139 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Eight years on, three new oncology drugs are proving to be the driving force for the new AstraZeneca: small molecule, targeted lung cancer drug Tagrisso (osimertinib) and ovarian cancer treatment Lynparza ... People who have BRCA gene mutations have an

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    There are two stand- out good news stories for AZ in 2018 – the growth of its cancer medicines portfolio and industry-leading sales expansion in China. ... Other key launches will include Lynparza, its ovarian cancer treatment, now co-marketed globally

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    and ovarian cancer, and some tumours such as pancreatic and prostate cancers have proved resistant to current immunotherapies. ... tumours. Researchers are also investigating whether preventive vaccines could be deployed in people with high-risk cancer

  • The tipping point The tipping point

    In 2016 alone, there were approximately 30 oncology drugs in late stage development for breast cancer, leukaemia, lung cancer and ovarian cancer.

  • AI’s potential in the pharma life cycle AI’s potential in the pharma life cycle

    Proactive intervention. Already AI is being used to identify women whose Twitter posts indicate they may have increased risk of developing two relatively rare diseases: ovarian cancer and cervical cancer.

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics